A Prospective Provincial Registry of 18 F-PSMA PET/CT for Recurrent Prostate Cancer: Results for 4,135 Men
Journal of Nuclear Medicine · 2025
DOI: 10.2967/jnumed.125.269653 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Nuclear Medicine, 2025. Verfasst von Andres Kohan und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Imaging, University of Toronto, Toronto, Ontario, Canada. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Positron Emission Tomography Computed Tomography, Registries, Glutamate Carboxypeptidase II. Die Arbeit nennt 39 Literaturangaben.
Abstract (Originalsprache)
The PSMA-PET Registry for Recurrent Prostate Cancer study was initiated in Ontario, Canada, to provide access to and characterize the performance of 18F-prostate-specific membrane antigen (PSMA) PET/CT among men with recurrent prostate cancer.
Methods
Between October 2018 and September 2022, 4,135 men were enrolled in PREP. Eligibility included suspected prostate cancer recurrence after prior definitive treatment (radical prostatectomy or radiotherapy). Men were enrolled in 1 of 6 predefined clinical cohorts and imaged with 18F-DCFPyL at 1 of 6 participating sites. Standardized reports delineated sites of recurrence and changes in disease management after PET/CT. Linkage to provincial databases allowed estimation of overall survival (OS) and use of salvage radiotherapy after PET/CT.
Results
The median follow-up was 1.8 y. Significant predictors of a positive PET/CT scan on multivariate analysis included a higher prostate-specific antigen level at the time of PET/CT and cohort (highest for cohort 4, whose cancer had progressed during salvage hormone therapy). Significant predictors of management change were type of recurrence (highest for isolated locoregional disease) and higher prostate-specific antigen level. Significant predictors of worse OS included cohort (worst for cohort 4) and extent and type of metastases (worst for mixed bone, lymph, and visceral or extensive metastases). A change in disease management after PET/CT was a significant independent predictor of improved OS rates.
Conclusion
PREP facilitated access to 18F-PSMA PET/CT and demonstrated high rates of disease detection. Significant factors associated with survival were clinical scenario, pattern of metastases, and change in disease management after 18F-PSMA PET/CT.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Imaging, University of Toronto, Toronto, Ontario, Canada.
- Division of Urology, Department of Surgery, Western University, London, Ontario, Canada.
- Acute and Hospital-Based Care, Ontario Health (Cancer Care Ontario), Toronto, Ontario, Canada.
- Department of Surgery, University of Toronto, Toronto, Ontario, Canada.
- Department of Surgery, McMaster University, Hamilton, Ontario, Canada.
- Department of Radiation Oncology, Thunder Bay Regional Health Sciences Centre, Thunder Bay, Ontario, Canada.
Zitieren
APA
Kohan, A., Metser, U., Luke, W., Rashid, M., Langer, D. L., MacCrostie, P., Green, B., Mak, V., Kulkarni, G. S., Finelli, A., Shayegan, B., Pautler, S. E., Klotz, L., Hagerty, M., Lavallée, L. T., Hildebrand, C., & Bauman, G. (2025). A Prospective Provincial Registry of 18 F-PSMA PET/CT for Recurrent Prostate Cancer: Results for 4,135 Men. Journal of Nuclear Medicine. https://doi.org/10.2967/jnumed.125.269653
Vancouver
Kohan A, Metser U, Luke W, Rashid M, Langer DL, MacCrostie P, et al. A Prospective Provincial Registry of 18 F-PSMA PET/CT for Recurrent Prostate Cancer: Results for 4,135 Men. Journal of Nuclear Medicine. 2025. doi:10.2967/jnumed.125.269653
BibTeX
@article{Kohan2025,
author = {Kohan, Andres and Metser, Ur and Luke, William and Rashid, Mohammed and Langer, Deanna L and MacCrostie, Pamela and Green, Bo and Mak, Victor and Kulkarni, Girish S and Finelli, Antonio and Shayegan, Bobby and Pautler, Stephen E and Klotz, Laurence and Hagerty, Marlon and Lavallée, Luke T and Hildebrand, Catherine and Bauman, Glenn},
title = {A Prospective Provincial Registry of 18 F-PSMA PET/CT for Recurrent Prostate Cancer: Results for 4,135 Men},
journal = {Journal of Nuclear Medicine},
year = {2025},
doi = {10.2967/jnumed.125.269653}
}
EUVIMED